Estimation of diagnosis and treatment costs of non-alcoholic fatty liver disease: A two-year observation

Hepatitis Monthly

Volumn 13, Issue 5, 2013, Pages

  Ghamar Chehreh, Mohammad Ebrahim ^a   Vahedi, Mohsen ^b   Pourhoseingholi, Mohammad Amin ^c   Ashtari, Sara ^c   Khedmat, Hossein ^a   Amin, Mohsen ^a   Reza Zali, Mohammad ^c   Moayed Alavian, Seyed ^a  

^a BAQIYATALLAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Costs and Cost Analysis; Delivery of Health Care; Non alcoholic Fatty Liver Disease; Utilization

Indexed keywords

AMINOTRANSFERASE;

ADULT; ARTICLE; BODY MASS; COMORBIDITY; CORONARY ARTERY DISEASE; COST BENEFIT ANALYSIS; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; HYPERTENSION; HYPOTHYROIDISM; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER;

EID: 84878369211     PISSN: 1735143X     EISSN: 17353408     Source Type: Journal    
DOI: 10.8512/hepatmon.7382     Document Type: Article

References (24)

1. Hajiaghamohammadi AA, Ziaee A, Samimi R. The efficacy of licorice root extract in decreasing transaminase activities in non-alcoholic fatty liver disease: a randomized controlled clinical trial. Phytother Res. 2012;26(9):1381-4. [DOI] [PubMed]
2. Sohrabpour AA, Rezvan H, Amini-Kafiabad S, Dayhim MR, Merat S, Pourshams A. Prevalence of nonalcoholic steatohepatitis in Iran: a population based study. Middle East J Digest Dis. 2011;2(1):14-9.
3. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology. 2003;37(5):1202-19. [DOI] [PubMed]
4. Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology. 2005;129(1):113-21. [PubMed]
5. Dam-Larsen S, Franzmann M, Andersen IB, Christoffersen P, Jensen LB, Sorensen TI, et al. Long term prognosis of fatty liver: risk of chronic liver disease and death. Gut. 2004;53(5):750-5. [PubMed]
6. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999;116(6):1413-9. [PubMed]
7. Teli MR, James OF, Burt AD, Bennett MK, Day CP. The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology. 1995;22(6):1714-9. [PubMed]
8. Cortez-Pinto H, Baptista A, Camilo ME, De Moura MC. Nonalcoholic steatohepatitis--a long-term follow-up study: comparison with alcoholic hepatitis in ambulatory and hospitalized patients. Dig Dis Sci. 2003;48(10):1909-13. [PubMed]
9. Lee RG. Nonalcoholic steatohepatitis: a study of 49 patients. Hum Pathol. 1989;20(6):594-8. [PubMed]
10. Powell EE, Cooksley WG, Hanson R, Searle J, Halliday JW, Powell LW. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology. 1990;11(1):74-80. [PubMed]
11. Neuschwander-Tetri BA. Nonalcoholic steatohepatitis and the metabolic syndrome. Am J Med Sci.2005;330(6):326-35. [PubMed]
12. Volzke H, Schwarz S, Baumeister SE, Wallaschofski H, Schwahn C, Grabe HJ, et al. Menopausal status and hepatic steatosis in a general female population. Gut. 2007;56(4):594-5. [DOI] [PubMed]
13. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003;37(4):917-23. [DOI] [PubMed]
14. Targher G. Non-alcoholic fatty liver disease, the metabolic syndrome and the risk of cardiovascular disease: the plot thickens. Diabet Med. 2007;24(1):1-6. [DOI] [PubMed]
15. Pagadala MR, McCullough AJ. Non-alcoholic fatty liver disease and obesity: not all about body mass index. Am J Gastroenterol. 2012;107(12):1859-61. [DOI] [PubMed]
16. Jamali R, Khonsari M, Merat S, Khoshnia M, Jafari E, Bahram Kalhori A, et al. Persistent alanine aminotransferase elevation among the general Iranian population: prevalence and causes. World J Gastroenterol. 2008;14(18):2867-71. [PubMed]
17. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2005;365(9468):1415-28. [DOI] [PubMed]
18. Medical Lows and Tariffs. The price list by Iranian cabinet of the public health centers. 2010; [updated 2010; cited 2010]; Available from: http://irteb.com
19. Iranian Ministry of Health and Medical Education. List of price of drugs. 2010; [updated 2010]; Available from:http://fdo.behdash.gov.ir
20. Trading Economic Website. 2010; Available from: http://tradingeconomic.com/ira.
21. Harrison SA, Fincke C, Helinski D, Torgerson S, Hayashi P. A pilot study of orlistat treatment in obese, non-alcoholic steatohepatitis patients. Aliment Pharmacol Ther. 2004;20(6):623-8. [DOI] [PubMed]
22. Petersen KF, Dufour S, Befroy D, Lehrke M, Hendler RE, Shulman GI. Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. Diabetes. 2005;54(3):603-8. [PubMed]
23. Pourshams A, Malekzadeh R, Monavvari A, Akbari MR, Mohamadkhani A, Yarahmadi S, et al. Prevalence and etiology of persistently elevated alanine aminotransferase levels in healthy Iranian blood donors. J Gastroenterol Hepatol. 2005;20(2):229-33. [DOI] [PubMed]
24. Iranian Databases of Census Publication 2010; [updated 2010]; Available from: http://amar.sci.org.ir